Important: New Login Process

We've updated our access and security system. The first time you log in, enter your work email, and we'll guide you through the process.

  • If your organization uses Single Sign-On (SSO), you will be redirected to your company's login portal.
  • If you log in with a username and password, you will be prompted to set a new password before accessing your account.

Go to the Login Page to get started.

We appreciate your cooperation during this transition. If you need assistance, please call +1 650-552-4224 or email support@biocentury.com.

BioCentury
  • Company Profiles
  • Target Profiles
  • Product Profiles
Explore BCIQ profiles by entering a target name.
BioCentury | Mar 21, 2019
Company News

FDA approves Jazz's Sunosi for daytime sleepiness

BioCentury | Feb 1, 2019
Product R&D

BlueRock’s PD purity play

Why BlueRock’s iPS cells could fare better in Parkinson’s than fetal transplants
BioCentury | Apr 20, 2017
Clinical News

Vyvanse regulatory update

BioCentury | Feb 16, 2017
Clinical News

JZP-110: Ph II started

BioCentury | Dec 16, 2016
Clinical News

HLD200 regulatory update

BioCentury | Jul 11, 2016
Clinical News

Benjorna: Phase III data

BioCentury | Sep 7, 2015
Clinical News

HLD-200: Phase III started

Items per page:
1 - 10 of 97